SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
AMLN (DIABETES DRUGS)
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
2173 62 0 AMLN
Emcee:  eric siegel Type:  Unmoderated
Introduction Market Data Compact
Does anyone follow this co?According to to Hambrect and Quist and Michael Murphy of Ca. Tech. this co. has a leg up in diabetes research and a strong partner in Johnson and Johnson.The stock has been moving up of late on big volume.Any info. would be appreciated
Eric
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2173bydureon approved. ugly, ugly experience.scaram(o)uche-1/27/2012
2172Thank goodness we have some sort of closure. I wonder what Carl is thinking. Herichardred-11/8/2011
2171Lilly-Amylin’s Diabetes Drug Wins Approval for Expanded Use richardred-10/20/2011
2170AMLN says - <i>accusing the larger drugmaker of breaking their commercialitom pope-5/16/2011
2169Amylin's Goal: Get Lilly to buy them out? I don't quite understand therkrw-5/16/2011
2168AP: <i>THE COMPLAINT: Amylin Pharmaceuticals Inc. said Monday it filed a tom pope-5/16/2011
2167<i>>Two or three months for a pop or drop.<</i> Actually, neiDewDiligence_on_SI-4/18/2011
2166Two or three months for a pop or drop. European committee endorses Bydureon forrichardred-4/17/2011
2165And the XOMA P2B trial in type 2 diabetes fails: Message 27256483 Cheers, Tuctuck-3/22/2011
2164Amylin and Takeda have suspended the Symlin/metreleptin obesity study due to an tuck-3/16/2011
2163Today's failure of Bydureon against Victoza led me to dig into the Takeda obtuck-3/3/2011
2162MannKind Becomes Poster Child For Dangers Of FDA Secrecy Jan. 20 2011 - 8:23 am richardred11/20/2011
2161And to you. Just saying I doubt X052 is AMLN's biggest threat. Of the two tuck-1/7/2011
2160TUCK, I own no shares of XOMA or Lexicon, but own shares of AMLN again, after a richardred-1/7/2011
2159>>Median reduction from baseline in hemoglobin A1c levels at day 84 was 0.tuck-1/7/2011
2158Xoma Ltd. (XOMA 6.78, +0.11, +1.65%) shares also fell, by 11% to $6.01. The corichardred-1/7/2011
2157>>Lexicon Announces Positive Results from New Clinical Study of LX4211 in tuck-1/6/2011
2156Rumsfeld tenure at Amylin covered here: investors.amylin.com The year of this tuck-12/6/2010
2155I had Amylin a long time ago and sold it a long time ago. My enquiry is about fEdward Boghosian-12/5/2010
2154Not gonna see LAR until 2012 at earliest. I was expecting something like this (tuck-10/20/2010
2153"Dragging Sales of Byetta Could Mean Trouble for Bydureon" Minyanvilltuck-7/22/2010
2152Ah, come on! It's Friday, and this is a government job. We're expectscaram(o)uche-3/12/2010
2151Aiming High for Amylin Pharmaceuticals Jesup & Lamont initiated coverage atPaul Lee23/5/2010
2150Color on today's upgrade from Barclay's (this would be a former Lehman atuck-11/24/2009
2149<i>Amylin To Live Large On The Fat Of The Land John Dobosz, 11.05.09, 01:5RealMuLan-11/5/2009
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News